Frontline Combo Yields High Remission Rate in Hairy Cell Leukemia

(MedPage Today) -- Use of the BRAF inhibitor vemurafenib (Zelboraf) combined with the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) led to high rates of complete remission as frontline therapy for patients with hairy cell leukemia in a small...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news